Annovis Given US Patent for Potential Parkinson’s Treatment Expected to Enter Phase 2 Trial

Annovis Given US Patent for Potential Parkinson’s Treatment Expected to Enter Phase 2 Trial
Annovis Bio’s lead investigative therapy ANVS401 (also known as Posiphen) targeting protein buildup in the brain has been granted a U.S. patent as a way of treating Parkinson’s disease, Lewy body dementia, and other Lewy body disorders. The company, previously known as QR Pharma, expects that multiple patents for ANVS401 will be generated from this patent family, each independent and ... read more
Source: Parkinson’s News TodayPublished on 2020-02-24By Patricia Inacio, PhD